- AIG Board OKs CEO Pay; Benmosche Agrees to Stay
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Deere Reports Quarterly Net Loss, Revenue Falls
- Tiffany Profit Higher Than Expected; Raises Outlook
- Americans Ditch Planes for Trains this Thanksgiving
- Obama Reiterates Commitment to Boost US-India Ties
- FDIC's Bair Cautions on Risks in Bank Break-Up Plan
- Call Me Crazy: Confessions of a Black Friday Shopper
- Turkey Day 101: How Well Do You Know Your Bird?
- Why You Should Play the Reflation Trade: Stock Picker
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Wednesday's Economic News Crunch Could Tilt Markets
- Obama Reiterates Commitment to Boost US-India Ties
- NBA D-League On The Rise
- Australia Wheat Exporters Face Challenges: GrainCorp
- Japan Export Rebound Eases Fear of New Recession
- Starbucks Eyes China as Next Major Market
- Stifling Anger at Work Can Kill, Survey Finds
- The Social Media Gaming Threat
Text Size 
The Food and Drug Administration on Friday approved a potential blockbuster drug from Johnson & Johnson that fights three forms of arthritis caused by immune-system disorders.
 |
CNBC.com |
The injectable medication called Simponi is essentially a follow-up to the multibillion-dollar drug Remicade, which is marketed in the U.S. by J&J and in Europe and other countries by Schering-Plough. Combined sales of the drug were over $5 billion last year.
Sales of the new drug would be similarly split between the two companies.
FDA regulators have approved the drug for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, a painful, progressive form of spinal arthritis. All three forms of arthritis are chronic disorders in which the immune system attacks joints, causing stiffness, pain and restricted motion.
The drug is injected under the skin once a month and is designed to be used alongside immune-system supressing drugs.
J&J [JNJ
Loading...
()
] and Schering have touted the drug as the new standard of so-called tumor necrosis factor blockers, a group of drugs that includes Wyeth [WYE
Loading...
()
] and Amgen's [AMGN
Loading...
()
] Enbrel and Abbott Laboratories' Humira. Unlike Simponi, those drugs are generally injected once every week or two weeks.
The drug class works by targeting and neutralizing a protein that, when overproduced, causes inflammation and damage to bones, cartilage and other tissue.
The moneymaking potential of Simponi and Remicade are among the reasons Merck, of Whitehouse Station, N.J., is acquiring Schering-Plough for $41.1 billion.
Merck [MRK
Loading...
()
] has structured its purchase of Kenilworth, N.J.-based Schering-Plough [SGP
Loading...
()
] as a reverse merger in hopes of avoiding change-of-control provisions in Schering's deal with J&J. Under those rules, marketing rights of Remicade would revert to J&J, wiping out the roughly $2 billion in profits that Schering makes from Remicade each year.
Simponi, known generically as golimumab, was discovered and developed by J&J's Centocor Ortho Biotech unit.
Shares of J&J fell 48 cents Friday to close at $50.92.
Print
Email
- Remember when auto shows were major events where new models could generate buzz?
- CNBC’s Mike Huckman visits a cutting-edge plant to see how the flu vaccine of the future is being made.
- People who bottle up their anger at work are up to five times more likely to suffer a heart attack, a study found.
- Playboy will outsource its publishing operations in a bid to become profitable again.
- A new McDonald's in Manhattan is the nation's first to sport a sleek, chic interior imported from stores in London and Paris.
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
Data is a real-time snapshot *Data is delayed at least 15 minutes